

Industry-led oncology trials may inflate costeffectiveness

December 11 2015



(HealthDay)—Pharmaceutical industry-sponsored studies are more likely to report favorable estimates in cost-effectiveness analysis (CEA) of drugs used in breast cancer treatment, according to a research letter published online Dec. 10 in *JAMA Oncology*.

Jordan D. Lane, M.D., from the Walter Reed National Military Medical Center in Bethesda, Md., and colleagues examined CEAs for <u>breast</u> <u>cancer</u> from the Tufts Cost-Effectiveness Analysis Registry. Independent associations between industry sponsorship and study results were estimated, after adjustment for drug class, cancer stage targeted, and study <u>quality</u> score.

The researchers found that 65 of the 105 CEA studies were industry funded. Industry-sponsored studies had nonsignificantly higher study



quality ratings (mean rating, 4.8 versus 4.4 for studies with other sponsorship; P = 0.09). Industry-sponsored studies were significantly more likely to report favorable cost-effectiveness results compared with other sponsored studies (75.4 versus 40.0 percent at \$50,000/quality-adjusted life-year [QALY]; P = 0.004). Industry-sponsored studies were more likely to report favorable findings among the subset of CEAs with high quality ratings (75.5 versus 45.5 percent; P = 0.04 at the \$50,000/QALY threshold).

"Our <u>analysis</u> of breast cancer CEAs suggests that pharmaceutical industry-sponsored studies continue to be more likely to report favorable estimates than studies with other sponsorship," the authors write.

More information: <u>Full Text (subscription or payment may be required)</u>

Copyright © 2015 HealthDay. All rights reserved.

Citation: Industry-led oncology trials may inflate cost-effectiveness (2015, December 11) retrieved 12 July 2023 from https://medicalxpress.com/news/2015-12-industry-led-oncology-trials-inflate-cost-effectiveness.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.